Mp52-16 Comparative Outcomes of Standard and Modified Radical Prostatectomy at 5-7 Years of Follow-Up

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy II (MP52)1 May 2024MP52-16 COMPARATIVE OUTCOMES OF STANDARD AND MODIFIED RADICAL PROSTATECTOMY AT 5-7 YEARS OF FOLLOW-UP Kaushik P. Kolanukuduru, Shane Tinsley, Akshay Sood, Firas F. Abdollah, Wooju Jeong, and Mani Menon Kaushik P. KolanukuduruKaushik P. Kolanukuduru , Shane TinsleyShane Tinsley , Akshay SoodAkshay Sood , Firas F. AbdollahFiras F. Abdollah , Wooju JeongWooju Jeong , and Mani MenonMani Menon View All Author Informationhttps://doi.org/10.1097/01.JU.0001008864.84854.b7.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Precision Prostatectomy (Precision Prostatectomy - MPP) is a form of surgical subtotal gland therapy that involves the removal of 90-95% of the prostate while preserving the capsule and the seminal vesicle contralateral to the dominant lesion. We present the oncological and functional outcomes at a median follow-up of 5 years in the first 100 patients undergoing MPP. We compare the results to a group of patients who were candidates for MPP but chose to undergo conventional radical prostatectomy (the modelling cohort - RP). METHODS: From 2017-2021, precision prostatectomy was offered to men with dominant unilateral cancer (Gleason ≤4+3) prostate cancer and a Prostate Specific Antigen (PSA) of ≤20 ng/ml, who placed a high priority on maintaining erectile function in an IRB-approved study. Patients who refused underwent a conventional radical prostatectomy, with removal of both seminal vesicles. The follow-up period was 5-7 years. RESULTS: There were 100 patients in each cohort. Table 1 lists the baseline characteristics of the two groups. The median age was 60 and 61.5 in both groups, these patients had a median follow-up of 60 months and 68.5 months. The median pre-operative PSA was 5.7 ng/ml and 5.3 ng/ml in the respective groups, and the PSA at the median follow-up was 0.04 ng/ml and <0.01 ng/ml respectively. The functional and oncological follow up is shown in the Figure 1. MPP was non-inferior to RP in the positive margin rates, freedom from secondary treatment, BCR or 12-month continence rates. However, MPP was superior to RP in the requirement for salvage radiation/hormones, early continence, and erectile function. CONCLUSIONS: The freedom from progression rates after MPP were comparable to RP in patients with intermediate-risk prostate cancer (88%, 91%). Recurrences after MPP were treated with excision of the remnant, whereas recurrences after RP were treated with radiation and hormone therapy. Download PPT Source of Funding: No sources of funding to disclose © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e859 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Kaushik P. Kolanukuduru More articles by this author Shane Tinsley More articles by this author Akshay Sood More articles by this author Firas F. Abdollah More articles by this author Wooju Jeong More articles by this author Mani Menon More articles by this author Expand All Advertisement PDF downloadLoading ...